| 标题 |
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Diabetes & Endocrinology 作者:Andrea M. Haqq; Wendy K. Chung; Hélène Dollfus; Robert Haws; Gabriel Ángel Martos‐Moreno; et al 出版日期:2022-11-07 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)